nodes	percent_of_prediction	percent_of_DWPC	metapath
Dabrafenib—SLC22A8—Doxycycline—malaria	0.102	0.144	CbGbCtD
Dabrafenib—SLC22A6—Doxycycline—malaria	0.0709	0.1	CbGbCtD
Dabrafenib—SLCO1B1—Quinidine—malaria	0.0659	0.0929	CbGbCtD
Dabrafenib—CYP2C8—Pyrimethamine—malaria	0.0616	0.0868	CbGbCtD
Dabrafenib—CYP2C8—Sulfadiazine—malaria	0.0616	0.0868	CbGbCtD
Dabrafenib—SLC22A8—Quinidine—malaria	0.0608	0.0858	CbGbCtD
Dabrafenib—CYP3A4—Clindamycin—malaria	0.0435	0.0613	CbGbCtD
Dabrafenib—CYP2C8—Quinine—malaria	0.0317	0.0447	CbGbCtD
Dabrafenib—CYP2C8—Quinidine—malaria	0.0279	0.0393	CbGbCtD
Dabrafenib—CYP3A4—Sulfadiazine—malaria	0.025	0.0352	CbGbCtD
Dabrafenib—CYP2C8—Dapsone—malaria	0.024	0.0339	CbGbCtD
Dabrafenib—ABCB1—Quinine—malaria	0.0215	0.0303	CbGbCtD
Dabrafenib—CYP3A4—Artemether—malaria	0.0212	0.0299	CbGbCtD
Dabrafenib—CYP3A4—Proguanil—malaria	0.02	0.0282	CbGbCtD
Dabrafenib—CYP3A4—Doxycycline—malaria	0.0189	0.0267	CbGbCtD
Dabrafenib—ABCB1—Quinidine—malaria	0.0189	0.0266	CbGbCtD
Dabrafenib—CYP3A4—Quinine—malaria	0.0129	0.0181	CbGbCtD
Dabrafenib—CYP3A4—Quinidine—malaria	0.0113	0.0159	CbGbCtD
Dabrafenib—CYP3A4—Dapsone—malaria	0.00975	0.0137	CbGbCtD
Dabrafenib—LIMK1—blood—malaria	0.00385	0.0489	CbGeAlD
Dabrafenib—NEK11—brain—malaria	0.00334	0.0424	CbGeAlD
Dabrafenib—SLCO1B1—blood plasma—malaria	0.00323	0.0411	CbGeAlD
Dabrafenib—SIK1—saliva-secreting gland—malaria	0.00315	0.04	CbGeAlD
Dabrafenib—SIK1—hematopoietic system—malaria	0.003	0.0382	CbGeAlD
Dabrafenib—RAF1—saliva-secreting gland—malaria	0.0025	0.0318	CbGeAlD
Dabrafenib—SIK1—kidney—malaria	0.00246	0.0313	CbGeAlD
Dabrafenib—RAF1—hematopoietic system—malaria	0.00239	0.0304	CbGeAlD
Dabrafenib—LIMK1—brain—malaria	0.00239	0.0303	CbGeAlD
Dabrafenib—BRAF—blood—malaria	0.00238	0.0302	CbGeAlD
Dabrafenib—BRAF—bone marrow—malaria	0.0023	0.0292	CbGeAlD
Dabrafenib—SIK1—blood—malaria	0.00199	0.0253	CbGeAlD
Dabrafenib—RAF1—kidney—malaria	0.00196	0.0249	CbGeAlD
Dabrafenib—SIK1—bone marrow—malaria	0.00193	0.0245	CbGeAlD
Dabrafenib—BRAF—liver—malaria	0.00186	0.0236	CbGeAlD
Dabrafenib—CYP2C8—blood plasma—malaria	0.00184	0.0234	CbGeAlD
Dabrafenib—SLCO1B1—hematopoietic system—malaria	0.00179	0.0227	CbGeAlD
Dabrafenib—RAF1—digestive system—malaria	0.00166	0.0211	CbGeAlD
Dabrafenib—SLCO1B3—liver—malaria	0.0016	0.0204	CbGeAlD
Dabrafenib—RAF1—blood—malaria	0.00158	0.0201	CbGeAlD
Dabrafenib—SIK1—liver—malaria	0.00156	0.0198	CbGeAlD
Dabrafenib—RAF1—bone marrow—malaria	0.00153	0.0195	CbGeAlD
Dabrafenib—BRAF—brain—malaria	0.00148	0.0187	CbGeAlD
Dabrafenib—SLCO1B1—kidney—malaria	0.00147	0.0186	CbGeAlD
Dabrafenib—SLC22A8—hematopoietic system—malaria	0.00139	0.0177	CbGeAlD
Dabrafenib—CYP3A4—blood plasma—malaria	0.00125	0.0158	CbGeAlD
Dabrafenib—SLCO1B1—digestive system—malaria	0.00124	0.0158	CbGeAlD
Dabrafenib—RAF1—liver—malaria	0.00124	0.0157	CbGeAlD
Dabrafenib—SIK1—brain—malaria	0.00123	0.0157	CbGeAlD
Dabrafenib—SLCO1B1—blood—malaria	0.00118	0.0151	CbGeAlD
Dabrafenib—SLC22A8—kidney—malaria	0.00114	0.0145	CbGeAlD
Dabrafenib—ABCG2—saliva-secreting gland—malaria	0.00104	0.0132	CbGeAlD
Dabrafenib—CYP2C8—hematopoietic system—malaria	0.00102	0.0129	CbGeAlD
Dabrafenib—RAF1—brain—malaria	0.000983	0.0125	CbGeAlD
Dabrafenib—Decreased appetite—Pyrimethamine—malaria	0.000957	0.00581	CcSEcCtD
Dabrafenib—SLC22A6—brain—malaria	0.000954	0.0121	CbGeAlD
Dabrafenib—SLCO1B1—liver—malaria	0.000927	0.0118	CbGeAlD
Dabrafenib—SLC22A8—blood—malaria	0.000921	0.0117	CbGeAlD
Dabrafenib—Cough—Proguanil—malaria	0.000917	0.00557	CcSEcCtD
Dabrafenib—Renal failure acute—Quinidine—malaria	0.000916	0.00556	CcSEcCtD
Dabrafenib—Renal failure acute—Quinine—malaria	0.000916	0.00556	CcSEcCtD
Dabrafenib—Dermatitis bullous—Clindamycin—malaria	0.000902	0.00548	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Proguanil—malaria	0.000888	0.00539	CcSEcCtD
Dabrafenib—Dermatitis bullous—Quinine—malaria	0.000885	0.00538	CcSEcCtD
Dabrafenib—Dermatitis bullous—Quinidine—malaria	0.000885	0.00538	CcSEcCtD
Dabrafenib—ABCB1—blood plasma—malaria	0.000882	0.0112	CbGeAlD
Dabrafenib—Stomatitis—Sulfadiazine—malaria	0.00087	0.00528	CcSEcCtD
Dabrafenib—Nervous system disorder—Proguanil—malaria	0.000841	0.00511	CcSEcCtD
Dabrafenib—CYP2C8—kidney—malaria	0.000834	0.0106	CbGeAlD
Dabrafenib—Skin disorder—Proguanil—malaria	0.000833	0.00506	CcSEcCtD
Dabrafenib—Renal failure acute—Quinidine barbiturate—malaria	0.000827	0.00502	CcSEcCtD
Dabrafenib—Hypersensitivity—Pyrimethamine—malaria	0.000811	0.00492	CcSEcCtD
Dabrafenib—Dermatitis bullous—Quinidine barbiturate—malaria	0.000799	0.00485	CcSEcCtD
Dabrafenib—Nasopharyngitis—Dapsone—malaria	0.000797	0.00484	CcSEcCtD
Dabrafenib—Dry skin—Clindamycin—malaria	0.00079	0.0048	CcSEcCtD
Dabrafenib—Abdominal pain upper—Clindamycin—malaria	0.000788	0.00478	CcSEcCtD
Dabrafenib—Abdominal pain upper—Quinidine—malaria	0.000773	0.00469	CcSEcCtD
Dabrafenib—Abdominal pain upper—Quinine—malaria	0.000773	0.00469	CcSEcCtD
Dabrafenib—Pancreatitis—Dapsone—malaria	0.000755	0.00459	CcSEcCtD
Dabrafenib—Decreased appetite—Proguanil—malaria	0.000745	0.00453	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Proguanil—malaria	0.00074	0.0045	CcSEcCtD
Dabrafenib—Chills—Sulfadiazine—malaria	0.000719	0.00437	CcSEcCtD
Dabrafenib—Abdominal discomfort—Clindamycin—malaria	0.000714	0.00434	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Proguanil—malaria	0.000701	0.00426	CcSEcCtD
Dabrafenib—Vomiting—Pyrimethamine—malaria	0.0007	0.00425	CcSEcCtD
Dabrafenib—Abdominal pain upper—Quinidine barbiturate—malaria	0.000697	0.00423	CcSEcCtD
Dabrafenib—Neutropenia—Clindamycin—malaria	0.000697	0.00423	CcSEcCtD
Dabrafenib—CYP3A4—hematopoietic system—malaria	0.000689	0.00875	CbGeAlD
Dabrafenib—Neutropenia—Quinidine—malaria	0.000684	0.00415	CcSEcCtD
Dabrafenib—Neutropenia—Quinine—malaria	0.000684	0.00415	CcSEcCtD
Dabrafenib—Abdominal pain—Proguanil—malaria	0.000678	0.00412	CcSEcCtD
Dabrafenib—Body temperature increased—Proguanil—malaria	0.000678	0.00412	CcSEcCtD
Dabrafenib—CYP2C8—blood—malaria	0.000674	0.00856	CbGeAlD
Dabrafenib—ABCG2—blood—malaria	0.000655	0.00832	CbGeAlD
Dabrafenib—Urinary tract infection—Clindamycin—malaria	0.000646	0.00392	CcSEcCtD
Dabrafenib—Renal failure—Quinidine—malaria	0.000641	0.00389	CcSEcCtD
Dabrafenib—Renal failure—Quinine—malaria	0.000641	0.00389	CcSEcCtD
Dabrafenib—ABCG2—bone marrow—malaria	0.000634	0.00805	CbGeAlD
Dabrafenib—Abdominal discomfort—Pentoxifylline—malaria	0.000631	0.00383	CcSEcCtD
Dabrafenib—Epistaxis—Clindamycin—malaria	0.000627	0.00381	CcSEcCtD
Dabrafenib—Leukopenia—Sulfadiazine—malaria	0.000624	0.00379	CcSEcCtD
Dabrafenib—Neutropenia—Quinidine barbiturate—malaria	0.000617	0.00375	CcSEcCtD
Dabrafenib—Arthralgia—Sulfadiazine—malaria	0.000594	0.00361	CcSEcCtD
Dabrafenib—Haemoglobin—Quinidine—malaria	0.000588	0.00357	CcSEcCtD
Dabrafenib—Haemoglobin—Quinine—malaria	0.000588	0.00357	CcSEcCtD
Dabrafenib—Infestation—Pentoxifylline—malaria	0.000587	0.00357	CcSEcCtD
Dabrafenib—Infestation NOS—Pentoxifylline—malaria	0.000587	0.00357	CcSEcCtD
Dabrafenib—Diarrhoea—Proguanil—malaria	0.000587	0.00356	CcSEcCtD
Dabrafenib—Haemorrhage—Quinidine—malaria	0.000585	0.00355	CcSEcCtD
Dabrafenib—Haemorrhage—Quinine—malaria	0.000585	0.00355	CcSEcCtD
Dabrafenib—Renal failure—Quinidine barbiturate—malaria	0.000578	0.00351	CcSEcCtD
Dabrafenib—Urinary tract disorder—Quinine—malaria	0.000578	0.00351	CcSEcCtD
Dabrafenib—Urinary tract disorder—Quinidine—malaria	0.000578	0.00351	CcSEcCtD
Dabrafenib—Urethral disorder—Quinidine—malaria	0.000574	0.00348	CcSEcCtD
Dabrafenib—Urethral disorder—Quinine—malaria	0.000574	0.00348	CcSEcCtD
Dabrafenib—SLC22A8—brain—malaria	0.000571	0.00726	CbGeAlD
Dabrafenib—CYP3A4—kidney—malaria	0.000565	0.00717	CbGeAlD
Dabrafenib—Thrombocytopenia—Sulfadiazine—malaria	0.000557	0.00338	CcSEcCtD
Dabrafenib—Epistaxis—Pentoxifylline—malaria	0.000554	0.00336	CcSEcCtD
Dabrafenib—Eye disorder—Quinine—malaria	0.000547	0.00332	CcSEcCtD
Dabrafenib—Eye disorder—Quinidine—malaria	0.000547	0.00332	CcSEcCtD
Dabrafenib—Vomiting—Proguanil—malaria	0.000545	0.00331	CcSEcCtD
Dabrafenib—Rash—Proguanil—malaria	0.000541	0.00328	CcSEcCtD
Dabrafenib—Dermatitis—Proguanil—malaria	0.00054	0.00328	CcSEcCtD
Dabrafenib—Headache—Proguanil—malaria	0.000537	0.00326	CcSEcCtD
Dabrafenib—Erythema—Dapsone—malaria	0.000537	0.00326	CcSEcCtD
Dabrafenib—Haemoglobin—Quinidine barbiturate—malaria	0.000531	0.00322	CcSEcCtD
Dabrafenib—Haemoglobin—Pentoxifylline—malaria	0.00053	0.00322	CcSEcCtD
Dabrafenib—Immune system disorder—Quinidine—malaria	0.000529	0.00321	CcSEcCtD
Dabrafenib—Immune system disorder—Quinine—malaria	0.000529	0.00321	CcSEcCtD
Dabrafenib—Haemorrhage—Quinidine barbiturate—malaria	0.000528	0.00321	CcSEcCtD
Dabrafenib—Mediastinal disorder—Quinine—malaria	0.000527	0.0032	CcSEcCtD
Dabrafenib—Mediastinal disorder—Quinidine—malaria	0.000527	0.0032	CcSEcCtD
Dabrafenib—Haemorrhage—Pentoxifylline—malaria	0.000527	0.0032	CcSEcCtD
Dabrafenib—CYP2C8—liver—malaria	0.000527	0.00669	CbGeAlD
Dabrafenib—Chills—Quinine—malaria	0.000525	0.00319	CcSEcCtD
Dabrafenib—Chills—Quinidine—malaria	0.000525	0.00319	CcSEcCtD
Dabrafenib—Urinary tract disorder—Quinidine barbiturate—malaria	0.000522	0.00317	CcSEcCtD
Dabrafenib—Erythema—Clindamycin—malaria	0.000519	0.00315	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Sulfadiazine—malaria	0.000519	0.00315	CcSEcCtD
Dabrafenib—Urethral disorder—Quinidine barbiturate—malaria	0.000518	0.00314	CcSEcCtD
Dabrafenib—Insomnia—Sulfadiazine—malaria	0.000515	0.00313	CcSEcCtD
Dabrafenib—Mental disorder—Quinidine—malaria	0.000513	0.00311	CcSEcCtD
Dabrafenib—Mental disorder—Quinine—malaria	0.000513	0.00311	CcSEcCtD
Dabrafenib—ABCG2—liver—malaria	0.000512	0.00651	CbGeAlD
Dabrafenib—Erythema—Quinine—malaria	0.000509	0.00309	CcSEcCtD
Dabrafenib—Malnutrition—Quinidine—malaria	0.000509	0.00309	CcSEcCtD
Dabrafenib—Erythema—Quinidine—malaria	0.000509	0.00309	CcSEcCtD
Dabrafenib—Malnutrition—Quinine—malaria	0.000509	0.00309	CcSEcCtD
Dabrafenib—Nausea—Proguanil—malaria	0.000509	0.00309	CcSEcCtD
Dabrafenib—Vision blurred—Dapsone—malaria	0.000506	0.00307	CcSEcCtD
Dabrafenib—Back pain—Clindamycin—malaria	0.000502	0.00305	CcSEcCtD
Dabrafenib—Muscle spasms—Clindamycin—malaria	0.000499	0.00303	CcSEcCtD
Dabrafenib—Decreased appetite—Sulfadiazine—malaria	0.000495	0.003	CcSEcCtD
Dabrafenib—Eye disorder—Quinidine barbiturate—malaria	0.000494	0.003	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Sulfadiazine—malaria	0.000491	0.00298	CcSEcCtD
Dabrafenib—ABCB1—hematopoietic system—malaria	0.000488	0.00619	CbGeAlD
Dabrafenib—Vision blurred—Quinine—malaria	0.00048	0.00292	CcSEcCtD
Dabrafenib—Vision blurred—Quinidine—malaria	0.00048	0.00292	CcSEcCtD
Dabrafenib—Anaemia—Clindamycin—malaria	0.00048	0.00292	CcSEcCtD
Dabrafenib—CYP3A4—digestive system—malaria	0.000479	0.00609	CbGeAlD
Dabrafenib—Immune system disorder—Quinidine barbiturate—malaria	0.000477	0.0029	CcSEcCtD
Dabrafenib—Immune system disorder—Pentoxifylline—malaria	0.000476	0.00289	CcSEcCtD
Dabrafenib—Mediastinal disorder—Quinidine barbiturate—malaria	0.000476	0.00289	CcSEcCtD
Dabrafenib—Chills—Quinidine barbiturate—malaria	0.000474	0.00288	CcSEcCtD
Dabrafenib—Arrhythmia—Pentoxifylline—malaria	0.000471	0.00286	CcSEcCtD
Dabrafenib—Cough—Dapsone—malaria	0.000468	0.00285	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Sulfadiazine—malaria	0.000465	0.00283	CcSEcCtD
Dabrafenib—Leukopenia—Clindamycin—malaria	0.000465	0.00282	CcSEcCtD
Dabrafenib—Mental disorder—Quinidine barbiturate—malaria	0.000463	0.00281	CcSEcCtD
Dabrafenib—Malnutrition—Quinidine barbiturate—malaria	0.00046	0.00279	CcSEcCtD
Dabrafenib—Erythema—Quinidine barbiturate—malaria	0.00046	0.00279	CcSEcCtD
Dabrafenib—Erythema—Pentoxifylline—malaria	0.000459	0.00279	CcSEcCtD
Dabrafenib—CYP3A4—blood—malaria	0.000456	0.0058	CbGeAlD
Dabrafenib—Leukopenia—Quinine—malaria	0.000456	0.00277	CcSEcCtD
Dabrafenib—Leukopenia—Quinidine—malaria	0.000456	0.00277	CcSEcCtD
Dabrafenib—Abdominal pain—Sulfadiazine—malaria	0.00045	0.00273	CcSEcCtD
Dabrafenib—Body temperature increased—Sulfadiazine—malaria	0.00045	0.00273	CcSEcCtD
Dabrafenib—Hypertension—Clindamycin—malaria	0.000448	0.00272	CcSEcCtD
Dabrafenib—Back pain—Pentoxifylline—malaria	0.000444	0.0027	CcSEcCtD
Dabrafenib—Muscle spasms—Pentoxifylline—malaria	0.000441	0.00268	CcSEcCtD
Dabrafenib—Myalgia—Quinidine—malaria	0.000434	0.00263	CcSEcCtD
Dabrafenib—Myalgia—Quinine—malaria	0.000434	0.00263	CcSEcCtD
Dabrafenib—Vision blurred—Quinidine barbiturate—malaria	0.000433	0.00263	CcSEcCtD
Dabrafenib—Vision blurred—Pentoxifylline—malaria	0.000433	0.00263	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Quinidine—malaria	0.000431	0.00262	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Quinine—malaria	0.000431	0.00262	CcSEcCtD
Dabrafenib—Anaemia—Pentoxifylline—malaria	0.000424	0.00258	CcSEcCtD
Dabrafenib—Hypersensitivity—Sulfadiazine—malaria	0.000419	0.00255	CcSEcCtD
Dabrafenib—CYP2C8—brain—malaria	0.000418	0.00531	CbGeAlD
Dabrafenib—Oedema—Quinidine—malaria	0.000416	0.00253	CcSEcCtD
Dabrafenib—Oedema—Quinine—malaria	0.000416	0.00253	CcSEcCtD
Dabrafenib—Thrombocytopenia—Clindamycin—malaria	0.000415	0.00252	CcSEcCtD
Dabrafenib—Leukopenia—Quinidine barbiturate—malaria	0.000412	0.0025	CcSEcCtD
Dabrafenib—Leukopenia—Pentoxifylline—malaria	0.000411	0.00249	CcSEcCtD
Dabrafenib—Nervous system disorder—Quinidine—malaria	0.000408	0.00248	CcSEcCtD
Dabrafenib—Nervous system disorder—Quinine—malaria	0.000408	0.00248	CcSEcCtD
Dabrafenib—Thrombocytopenia—Quinine—malaria	0.000407	0.00247	CcSEcCtD
Dabrafenib—Thrombocytopenia—Quinidine—malaria	0.000407	0.00247	CcSEcCtD
Dabrafenib—ABCG2—brain—malaria	0.000407	0.00516	CbGeAlD
Dabrafenib—Skin disorder—Quinidine—malaria	0.000404	0.00245	CcSEcCtD
Dabrafenib—Skin disorder—Quinine—malaria	0.000404	0.00245	CcSEcCtD
Dabrafenib—Pruritus—Sulfadiazine—malaria	0.000403	0.00245	CcSEcCtD
Dabrafenib—Hyperhidrosis—Quinine—malaria	0.000402	0.00244	CcSEcCtD
Dabrafenib—Hyperhidrosis—Quinidine—malaria	0.000402	0.00244	CcSEcCtD
Dabrafenib—ABCB1—kidney—malaria	0.0004	0.00508	CbGeAlD
Dabrafenib—Insomnia—Dapsone—malaria	0.000396	0.00241	CcSEcCtD
Dabrafenib—Hypertension—Pentoxifylline—malaria	0.000396	0.00241	CcSEcCtD
Dabrafenib—Hypotension—Clindamycin—malaria	0.000396	0.00241	CcSEcCtD
Dabrafenib—Myalgia—Quinidine barbiturate—malaria	0.000391	0.00238	CcSEcCtD
Dabrafenib—Arthralgia—Quinidine barbiturate—malaria	0.000391	0.00238	CcSEcCtD
Dabrafenib—Myalgia—Pentoxifylline—malaria	0.000391	0.00237	CcSEcCtD
Dabrafenib—Diarrhoea—Sulfadiazine—malaria	0.000389	0.00237	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Quinidine barbiturate—malaria	0.000389	0.00236	CcSEcCtD
Dabrafenib—Hypotension—Quinine—malaria	0.000389	0.00236	CcSEcCtD
Dabrafenib—Hypotension—Quinidine—malaria	0.000389	0.00236	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Pentoxifylline—malaria	0.000388	0.00236	CcSEcCtD
Dabrafenib—Dry mouth—Pentoxifylline—malaria	0.000382	0.00232	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Quinine—malaria	0.000379	0.0023	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Quinidine—malaria	0.000379	0.0023	CcSEcCtD
Dabrafenib—Oedema—Quinidine barbiturate—malaria	0.000375	0.00228	CcSEcCtD
Dabrafenib—Oedema—Pentoxifylline—malaria	0.000375	0.00227	CcSEcCtD
Dabrafenib—Infection—Pentoxifylline—malaria	0.000372	0.00226	CcSEcCtD
Dabrafenib—Nervous system disorder—Quinidine barbiturate—malaria	0.000368	0.00223	CcSEcCtD
Dabrafenib—Thrombocytopenia—Quinidine barbiturate—malaria	0.000367	0.00223	CcSEcCtD
Dabrafenib—Thrombocytopenia—Pentoxifylline—malaria	0.000367	0.00223	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Clindamycin—malaria	0.000366	0.00222	CcSEcCtD
Dabrafenib—Fatigue—Clindamycin—malaria	0.000365	0.00222	CcSEcCtD
Dabrafenib—Skin disorder—Quinidine barbiturate—malaria	0.000364	0.00221	CcSEcCtD
Dabrafenib—Skin disorder—Pentoxifylline—malaria	0.000364	0.00221	CcSEcCtD
Dabrafenib—Hyperhidrosis—Quinidine barbiturate—malaria	0.000363	0.0022	CcSEcCtD
Dabrafenib—Constipation—Clindamycin—malaria	0.000362	0.0022	CcSEcCtD
Dabrafenib—Hyperhidrosis—Pentoxifylline—malaria	0.000362	0.0022	CcSEcCtD
Dabrafenib—Vomiting—Sulfadiazine—malaria	0.000362	0.0022	CcSEcCtD
Dabrafenib—Decreased appetite—Quinidine—malaria	0.000361	0.0022	CcSEcCtD
Dabrafenib—Decreased appetite—Quinine—malaria	0.000361	0.0022	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Quinine—malaria	0.000359	0.00218	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Quinidine—malaria	0.000359	0.00218	CcSEcCtD
Dabrafenib—Rash—Sulfadiazine—malaria	0.000359	0.00218	CcSEcCtD
Dabrafenib—Dermatitis—Sulfadiazine—malaria	0.000359	0.00218	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Dapsone—malaria	0.000358	0.00218	CcSEcCtD
Dabrafenib—CYP3A4—liver—malaria	0.000357	0.00453	CbGeAlD
Dabrafenib—Headache—Sulfadiazine—malaria	0.000357	0.00217	CcSEcCtD
Dabrafenib—Hypotension—Quinidine barbiturate—malaria	0.000351	0.00213	CcSEcCtD
Dabrafenib—Hypotension—Pentoxifylline—malaria	0.00035	0.00213	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Clindamycin—malaria	0.000347	0.0021	CcSEcCtD
Dabrafenib—Body temperature increased—Dapsone—malaria	0.000346	0.0021	CcSEcCtD
Dabrafenib—Abdominal pain—Dapsone—malaria	0.000346	0.0021	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Quinidine barbiturate—malaria	0.000342	0.00208	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Pentoxifylline—malaria	0.000341	0.00207	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Quinidine—malaria	0.00034	0.00206	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Quinine—malaria	0.00034	0.00206	CcSEcCtD
Dabrafenib—ABCB1—digestive system—malaria	0.000339	0.00431	CbGeAlD
Dabrafenib—Insomnia—Pentoxifylline—malaria	0.000339	0.00206	CcSEcCtD
Dabrafenib—Nausea—Sulfadiazine—malaria	0.000338	0.00205	CcSEcCtD
Dabrafenib—Abdominal pain—Clindamycin—malaria	0.000335	0.00203	CcSEcCtD
Dabrafenib—Body temperature increased—Clindamycin—malaria	0.000335	0.00203	CcSEcCtD
Dabrafenib—Abdominal pain—Quinidine—malaria	0.000329	0.002	CcSEcCtD
Dabrafenib—Body temperature increased—Quinine—malaria	0.000329	0.002	CcSEcCtD
Dabrafenib—Body temperature increased—Quinidine—malaria	0.000329	0.002	CcSEcCtD
Dabrafenib—Abdominal pain—Quinine—malaria	0.000329	0.002	CcSEcCtD
Dabrafenib—Decreased appetite—Quinidine barbiturate—malaria	0.000326	0.00198	CcSEcCtD
Dabrafenib—Decreased appetite—Pentoxifylline—malaria	0.000326	0.00198	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Quinidine barbiturate—malaria	0.000324	0.00197	CcSEcCtD
Dabrafenib—ABCB1—blood—malaria	0.000323	0.0041	CbGeAlD
Dabrafenib—Constipation—Quinidine barbiturate—malaria	0.000321	0.00195	CcSEcCtD
Dabrafenib—Constipation—Pentoxifylline—malaria	0.00032	0.00195	CcSEcCtD
Dabrafenib—ABCB1—bone marrow—malaria	0.000313	0.00397	CbGeAlD
Dabrafenib—Hypersensitivity—Clindamycin—malaria	0.000312	0.0019	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Quinidine barbiturate—malaria	0.000307	0.00186	CcSEcCtD
Dabrafenib—Hypersensitivity—Quinine—malaria	0.000306	0.00186	CcSEcCtD
Dabrafenib—Hypersensitivity—Quinidine—malaria	0.000306	0.00186	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Pentoxifylline—malaria	0.000306	0.00186	CcSEcCtD
Dabrafenib—Asthenia—Clindamycin—malaria	0.000304	0.00185	CcSEcCtD
Dabrafenib—Pruritus—Clindamycin—malaria	0.0003	0.00182	CcSEcCtD
Dabrafenib—Asthenia—Quinine—malaria	0.000298	0.00181	CcSEcCtD
Dabrafenib—Asthenia—Quinidine—malaria	0.000298	0.00181	CcSEcCtD
Dabrafenib—Abdominal pain—Quinidine barbiturate—malaria	0.000297	0.0018	CcSEcCtD
Dabrafenib—Body temperature increased—Quinidine barbiturate—malaria	0.000297	0.0018	CcSEcCtD
Dabrafenib—Abdominal pain—Pentoxifylline—malaria	0.000296	0.0018	CcSEcCtD
Dabrafenib—Body temperature increased—Pentoxifylline—malaria	0.000296	0.0018	CcSEcCtD
Dabrafenib—Pruritus—Quinidine—malaria	0.000294	0.00179	CcSEcCtD
Dabrafenib—Pruritus—Quinine—malaria	0.000294	0.00179	CcSEcCtD
Dabrafenib—Diarrhoea—Clindamycin—malaria	0.00029	0.00176	CcSEcCtD
Dabrafenib—Diarrhoea—Quinidine—malaria	0.000284	0.00173	CcSEcCtD
Dabrafenib—Diarrhoea—Quinine—malaria	0.000284	0.00173	CcSEcCtD
Dabrafenib—Dizziness—Clindamycin—malaria	0.00028	0.0017	CcSEcCtD
Dabrafenib—Vomiting—Dapsone—malaria	0.000279	0.00169	CcSEcCtD
Dabrafenib—Hypersensitivity—Quinidine barbiturate—malaria	0.000276	0.00168	CcSEcCtD
Dabrafenib—Hypersensitivity—Pentoxifylline—malaria	0.000276	0.00168	CcSEcCtD
Dabrafenib—Dizziness—Quinine—malaria	0.000275	0.00167	CcSEcCtD
Dabrafenib—Dizziness—Quinidine—malaria	0.000275	0.00167	CcSEcCtD
Dabrafenib—Headache—Dapsone—malaria	0.000274	0.00167	CcSEcCtD
Dabrafenib—Vomiting—Clindamycin—malaria	0.000269	0.00164	CcSEcCtD
Dabrafenib—Asthenia—Quinidine barbiturate—malaria	0.000269	0.00164	CcSEcCtD
Dabrafenib—Asthenia—Pentoxifylline—malaria	0.000269	0.00163	CcSEcCtD
Dabrafenib—Rash—Clindamycin—malaria	0.000267	0.00162	CcSEcCtD
Dabrafenib—Dermatitis—Clindamycin—malaria	0.000267	0.00162	CcSEcCtD
Dabrafenib—Headache—Clindamycin—malaria	0.000266	0.00161	CcSEcCtD
Dabrafenib—Pruritus—Quinidine barbiturate—malaria	0.000265	0.00161	CcSEcCtD
Dabrafenib—Pruritus—Pentoxifylline—malaria	0.000265	0.00161	CcSEcCtD
Dabrafenib—Vomiting—Quinidine—malaria	0.000264	0.00161	CcSEcCtD
Dabrafenib—Vomiting—Quinine—malaria	0.000264	0.00161	CcSEcCtD
Dabrafenib—Rash—Quinidine—malaria	0.000262	0.00159	CcSEcCtD
Dabrafenib—Rash—Quinine—malaria	0.000262	0.00159	CcSEcCtD
Dabrafenib—Dermatitis—Quinidine—malaria	0.000262	0.00159	CcSEcCtD
Dabrafenib—Dermatitis—Quinine—malaria	0.000262	0.00159	CcSEcCtD
Dabrafenib—Headache—Quinidine—malaria	0.00026	0.00158	CcSEcCtD
Dabrafenib—Headache—Quinine—malaria	0.00026	0.00158	CcSEcCtD
Dabrafenib—Nausea—Dapsone—malaria	0.00026	0.00158	CcSEcCtD
Dabrafenib—Diarrhoea—Quinidine barbiturate—malaria	0.000257	0.00156	CcSEcCtD
Dabrafenib—Diarrhoea—Pentoxifylline—malaria	0.000256	0.00156	CcSEcCtD
Dabrafenib—ABCB1—liver—malaria	0.000253	0.00321	CbGeAlD
Dabrafenib—Nausea—Clindamycin—malaria	0.000252	0.00153	CcSEcCtD
Dabrafenib—Dizziness—Quinidine barbiturate—malaria	0.000248	0.00151	CcSEcCtD
Dabrafenib—Dizziness—Pentoxifylline—malaria	0.000248	0.0015	CcSEcCtD
Dabrafenib—Nausea—Quinine—malaria	0.000247	0.0015	CcSEcCtD
Dabrafenib—Nausea—Quinidine—malaria	0.000247	0.0015	CcSEcCtD
Dabrafenib—Vomiting—Quinidine barbiturate—malaria	0.000239	0.00145	CcSEcCtD
Dabrafenib—Vomiting—Pentoxifylline—malaria	0.000238	0.00145	CcSEcCtD
Dabrafenib—Rash—Quinidine barbiturate—malaria	0.000237	0.00144	CcSEcCtD
Dabrafenib—Dermatitis—Quinidine barbiturate—malaria	0.000236	0.00144	CcSEcCtD
Dabrafenib—Rash—Pentoxifylline—malaria	0.000236	0.00143	CcSEcCtD
Dabrafenib—Dermatitis—Pentoxifylline—malaria	0.000236	0.00143	CcSEcCtD
Dabrafenib—Headache—Quinidine barbiturate—malaria	0.000235	0.00143	CcSEcCtD
Dabrafenib—Headache—Pentoxifylline—malaria	0.000235	0.00143	CcSEcCtD
Dabrafenib—Nausea—Quinidine barbiturate—malaria	0.000223	0.00135	CcSEcCtD
Dabrafenib—Nausea—Pentoxifylline—malaria	0.000222	0.00135	CcSEcCtD
Dabrafenib—ABCB1—brain—malaria	0.0002	0.00255	CbGeAlD
Dabrafenib—LIMK1—Immune System—FCGR2A—malaria	0.000121	0.00253	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—PKLR—malaria	0.000119	0.0025	CbGpPWpGaD
Dabrafenib—LIMK1—Innate Immune System—CD36—malaria	0.000119	0.0025	CbGpPWpGaD
Dabrafenib—RAF1—Leptin signaling pathway—IL1B—malaria	0.000119	0.00249	CbGpPWpGaD
Dabrafenib—LIMK1—Developmental Biology—KDR—malaria	0.000117	0.00245	CbGpPWpGaD
Dabrafenib—ABCG2—Transmembrane transport of small molecules—SLC4A1—malaria	0.000117	0.00245	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—TIRAP—malaria	0.000113	0.00238	CbGpPWpGaD
Dabrafenib—RAF1—TCR Signaling Pathway—CD4—malaria	0.000111	0.00233	CbGpPWpGaD
Dabrafenib—RAF1—TWEAK Signaling Pathway—IL6—malaria	0.000111	0.00232	CbGpPWpGaD
Dabrafenib—RAF1—Cardiac Hypertrophic Response—TNF—malaria	0.00011	0.00232	CbGpPWpGaD
Dabrafenib—RAF1—FCERI mediated MAPK activation—IL6—malaria	0.000109	0.00228	CbGpPWpGaD
Dabrafenib—RAF1—DAP12 interactions—HLA-B—malaria	0.000108	0.00227	CbGpPWpGaD
Dabrafenib—LIMK1—Innate Immune System—CRP—malaria	0.000108	0.00226	CbGpPWpGaD
Dabrafenib—RAF1—Signalling to ERKs—IL6—malaria	0.000107	0.00223	CbGpPWpGaD
Dabrafenib—RAF1—FRS2-mediated cascade—IL6—malaria	0.000107	0.00223	CbGpPWpGaD
Dabrafenib—RAF1—MAPK Signaling Pathway—FAS—malaria	0.000106	0.00223	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—CR1—malaria	0.000105	0.00221	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—DHODH—malaria	0.000103	0.00217	CbGpPWpGaD
Dabrafenib—LIMK1—Innate Immune System—TLR4—malaria	0.000103	0.00216	CbGpPWpGaD
Dabrafenib—RAF1—TCR Signaling Pathway—IL1B—malaria	0.000103	0.00215	CbGpPWpGaD
Dabrafenib—ABCB1—Allograft Rejection—CD40LG—malaria	0.000102	0.00215	CbGpPWpGaD
Dabrafenib—ABCB1—Allograft Rejection—IL10—malaria	0.000102	0.00215	CbGpPWpGaD
Dabrafenib—CYP2C8—Biological oxidations—HPGDS—malaria	0.000102	0.00214	CbGpPWpGaD
Dabrafenib—RAF1—Senescence and Autophagy in Cancer—IFNG—malaria	0.000102	0.00213	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism of lipids and lipoproteins—HPGDS—malaria	0.000102	0.00213	CbGpPWpGaD
Dabrafenib—RAF1—Interleukin-2 signaling—IL6—malaria	0.000101	0.00212	CbGpPWpGaD
Dabrafenib—RAF1—Corticotropin-releasing hormone—IL2—malaria	0.0001	0.00211	CbGpPWpGaD
Dabrafenib—ABCB1—Allograft Rejection—IL4—malaria	9.96e-05	0.00209	CbGpPWpGaD
Dabrafenib—ABCB1—Allograft Rejection—HLA-B—malaria	9.74e-05	0.00204	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—FAS—malaria	9.61e-05	0.00201	CbGpPWpGaD
Dabrafenib—RAF1—Downstream signaling in naïve CD8+ T cells—TNF—malaria	9.55e-05	0.002	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism of lipids and lipoproteins—SCARB1—malaria	9.33e-05	0.00196	CbGpPWpGaD
Dabrafenib—ABCB1—Allograft Rejection—FAS—malaria	9.18e-05	0.00192	CbGpPWpGaD
Dabrafenib—RAF1—Senescence and Autophagy in Cancer—IL1B—malaria	9.07e-05	0.0019	CbGpPWpGaD
Dabrafenib—ABCB1—HIF-1-alpha transcription factor network—NOS2—malaria	9.07e-05	0.0019	CbGpPWpGaD
Dabrafenib—BRAF—MAPK Signaling Pathway—IL1B—malaria	9e-05	0.00189	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—TLR9—malaria	8.96e-05	0.00188	CbGpPWpGaD
Dabrafenib—RAF1—Platelet activation, signaling and aggregation—CD36—malaria	8.9e-05	0.00186	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by Interleukins—IL1B—malaria	8.87e-05	0.00186	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by Interleukins—IL2—malaria	8.84e-05	0.00185	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—SLC4A1—malaria	8.78e-05	0.00184	CbGpPWpGaD
Dabrafenib—RAF1—Focal Adhesion—KDR—malaria	8.68e-05	0.00182	CbGpPWpGaD
Dabrafenib—RAF1—SHP2 signaling—IL6—malaria	8.54e-05	0.00179	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—DECR1—malaria	8.26e-05	0.00173	CbGpPWpGaD
Dabrafenib—BRAF—Disease—PKLR—malaria	8.19e-05	0.00172	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—HPGDS—malaria	8.18e-05	0.00172	CbGpPWpGaD
Dabrafenib—RAF1—Cytokine Signaling in Immune system—IL18—malaria	7.92e-05	0.00166	CbGpPWpGaD
Dabrafenib—RAF1—MicroRNAs in cardiomyocyte hypertrophy—TNF—malaria	7.87e-05	0.00165	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CISH—malaria	7.85e-05	0.00164	CbGpPWpGaD
Dabrafenib—BRAF—Senescence and Autophagy in Cancer—IL6—malaria	7.68e-05	0.00161	CbGpPWpGaD
Dabrafenib—RAF1—NCAM signaling for neurite out-growth—IL6—malaria	7.52e-05	0.00158	CbGpPWpGaD
Dabrafenib—RAF1—Cytokine Signaling in Immune system—HLA-B—malaria	7.51e-05	0.00157	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—IL18—malaria	7.48e-05	0.00157	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—HBB—malaria	7.47e-05	0.00157	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—CD40LG—malaria	7.45e-05	0.00156	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—FCGR2B—malaria	7.41e-05	0.00155	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—CD8A—malaria	7.37e-05	0.00154	CbGpPWpGaD
Dabrafenib—RAF1—TNF alpha Signaling Pathway—TNF—malaria	7.32e-05	0.00153	CbGpPWpGaD
Dabrafenib—BRAF—Disease—G6PD—malaria	7.3e-05	0.00153	CbGpPWpGaD
Dabrafenib—LIMK1—Innate Immune System—CD4—malaria	7.27e-05	0.00152	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—FCGR2A—malaria	7.16e-05	0.0015	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—DECR1—malaria	7.16e-05	0.0015	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—HLA-B—malaria	7.09e-05	0.00149	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—ACKR1—malaria	7.09e-05	0.00149	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—CD36—malaria	6.95e-05	0.00146	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—DHODH—malaria	6.94e-05	0.00145	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism of lipids and lipoproteins—HPGDS—malaria	6.82e-05	0.00143	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—PKLR—malaria	6.66e-05	0.0014	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—TIRAP—malaria	6.6e-05	0.00138	CbGpPWpGaD
Dabrafenib—BRAF—MAPK Signaling Pathway—TNF—malaria	6.53e-05	0.00137	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—DHODH—malaria	6.43e-05	0.00135	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—SLC4A1—malaria	6.31e-05	0.00132	CbGpPWpGaD
Dabrafenib—RAF1—IRS-mediated signalling—IL6—malaria	6.29e-05	0.00132	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—CRP—malaria	6.27e-05	0.00131	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism of lipids and lipoproteins—SCARB1—malaria	6.27e-05	0.00131	CbGpPWpGaD
Dabrafenib—LIMK1—Axon guidance—IL6—malaria	6.24e-05	0.00131	CbGpPWpGaD
Dabrafenib—RAF1—MAPK Signaling Pathway—IL1B—malaria	6.23e-05	0.00131	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CR1—malaria	6.14e-05	0.00129	CbGpPWpGaD
Dabrafenib—RAF1—IRS-related events—IL6—malaria	6.12e-05	0.00128	CbGpPWpGaD
Dabrafenib—RAF1—Cytokine Signaling in Immune system—ICAM1—malaria	6.1e-05	0.00128	CbGpPWpGaD
Dabrafenib—RAF1—IRS-related events triggered by IGF1R—IL6—malaria	6.06e-05	0.00127	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—ACKR1—malaria	6.05e-05	0.00127	CbGpPWpGaD
Dabrafenib—ABCB1—Allograft Rejection—IFNG—malaria	6.02e-05	0.00126	CbGpPWpGaD
Dabrafenib—RAF1—TCR Signaling Pathway—IL6—malaria	6.01e-05	0.00126	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—TLR4—malaria	6.01e-05	0.00126	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—G6PD—malaria	5.93e-05	0.00124	CbGpPWpGaD
Dabrafenib—RAF1—IGF1R signaling cascade—IL6—malaria	5.91e-05	0.00124	CbGpPWpGaD
Dabrafenib—RAF1—Insulin receptor signalling cascade—IL6—malaria	5.91e-05	0.00124	CbGpPWpGaD
Dabrafenib—RAF1—TNF alpha Signaling Pathway—IL6—malaria	5.91e-05	0.00124	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—SLC4A1—malaria	5.9e-05	0.00124	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism of lipids and lipoproteins—CD36—malaria	5.85e-05	0.00123	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—ICAM1—malaria	5.76e-05	0.00121	CbGpPWpGaD
Dabrafenib—RAF1—Disease—PKLR—malaria	5.67e-05	0.00119	CbGpPWpGaD
Dabrafenib—RAF1—Axon guidance—KDR—malaria	5.66e-05	0.00119	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—DECR1—malaria	5.55e-05	0.00116	CbGpPWpGaD
Dabrafenib—LIMK1—Developmental Biology—TNF—malaria	5.51e-05	0.00116	CbGpPWpGaD
Dabrafenib—CYP3A4—Biological oxidations—HPGDS—malaria	5.48e-05	0.00115	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—SLC4A1—malaria	5.46e-05	0.00115	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by FGFR—IL6—malaria	5.43e-05	0.00114	CbGpPWpGaD
Dabrafenib—ABCB1—Allograft Rejection—IL1B—malaria	5.37e-05	0.00113	CbGpPWpGaD
Dabrafenib—ABCB1—Allograft Rejection—IL2—malaria	5.35e-05	0.00112	CbGpPWpGaD
Dabrafenib—RAF1—Senescence and Autophagy in Cancer—IL6—malaria	5.31e-05	0.00111	CbGpPWpGaD
Dabrafenib—RAF1—VEGFA-VEGFR2 Pathway—IL6—malaria	5.23e-05	0.0011	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—TLR9—malaria	5.22e-05	0.00109	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by Interleukins—IL6—malaria	5.19e-05	0.00109	CbGpPWpGaD
Dabrafenib—BRAF—Disease—DHFR—malaria	5.17e-05	0.00108	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—DECR1—malaria	5.14e-05	0.00108	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by FGFR in disease—IL6—malaria	5.06e-05	0.00106	CbGpPWpGaD
Dabrafenib—RAF1—Disease—G6PD—malaria	5.05e-05	0.00106	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—HBB—malaria	5.02e-05	0.00105	CbGpPWpGaD
Dabrafenib—RAF1—Platelet activation, signaling and aggregation—IL2—malaria	4.98e-05	0.00104	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by VEGF—IL6—malaria	4.94e-05	0.00104	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by Insulin receptor—IL6—malaria	4.91e-05	0.00103	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—TLR9—malaria	4.88e-05	0.00102	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—CD36—malaria	4.67e-05	0.00098	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—HBB—malaria	4.65e-05	0.000974	CbGpPWpGaD
Dabrafenib—RAF1—Cytokine Signaling in Immune system—IFNG—malaria	4.64e-05	0.000973	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—CD36—malaria	4.59e-05	0.000961	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—malaria	4.53e-05	0.00095	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—HPGDS—malaria	4.52e-05	0.000948	CbGpPWpGaD
Dabrafenib—RAF1—MAPK Signaling Pathway—TNF—malaria	4.52e-05	0.000948	CbGpPWpGaD
Dabrafenib—BRAF—NGF signalling via TRKA from the plasma membrane—IL6—malaria	4.48e-05	0.000939	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PKLR—malaria	4.47e-05	0.000937	CbGpPWpGaD
Dabrafenib—LIMK1—Developmental Biology—IL6—malaria	4.45e-05	0.000933	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—IFNG—malaria	4.38e-05	0.000919	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—CD40LG—malaria	4.25e-05	0.000891	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—CD4—malaria	4.23e-05	0.000887	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—HLA-B—malaria	4.21e-05	0.000883	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—CD8A—malaria	4.2e-05	0.000881	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by SCF-KIT—IL6—malaria	4.2e-05	0.00088	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—DHFR—malaria	4.2e-05	0.00088	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—ACKR1—malaria	4.19e-05	0.000878	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—FCGR2A—malaria	4.17e-05	0.000875	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—SCARB1—malaria	4.15e-05	0.000871	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PKLR—malaria	4.14e-05	0.000868	CbGpPWpGaD
Dabrafenib—RAF1—Cytokine Signaling in Immune system—IL1B—malaria	4.14e-05	0.000868	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—CD36—malaria	4.13e-05	0.000865	CbGpPWpGaD
Dabrafenib—RAF1—Cytokine Signaling in Immune system—IL2—malaria	4.12e-05	0.000865	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—TNF—malaria	4.08e-05	0.000855	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—HLA-B—malaria	4.04e-05	0.000848	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—KDR—malaria	4.04e-05	0.000847	CbGpPWpGaD
Dabrafenib—RAF1—Downstream signaling of activated FGFR—IL6—malaria	4.02e-05	0.000842	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—DHODH—malaria	3.99e-05	0.000836	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—G6PD—malaria	3.99e-05	0.000835	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—CD36—malaria	3.96e-05	0.000831	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by ERBB4—IL6—malaria	3.95e-05	0.000829	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism of lipids and lipoproteins—CD36—malaria	3.93e-05	0.000824	CbGpPWpGaD
Dabrafenib—LIMK1—Innate Immune System—IL6—malaria	3.93e-05	0.000824	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—HPGDS—malaria	3.92e-05	0.000822	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—IL1B—malaria	3.91e-05	0.00082	CbGpPWpGaD
Dabrafenib—ABCB1—Allograft Rejection—TNF—malaria	3.9e-05	0.000817	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—IL2—malaria	3.89e-05	0.000816	CbGpPWpGaD
Dabrafenib—RAF1—Downstream signal transduction—IL6—malaria	3.77e-05	0.000791	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—NOS2—malaria	3.77e-05	0.00079	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by FGFR—IL6—malaria	3.76e-05	0.000787	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by ERBB2—IL6—malaria	3.74e-05	0.000783	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—CRP—malaria	3.72e-05	0.00078	CbGpPWpGaD
Dabrafenib—RAF1—DAP12 signaling—IL6—malaria	3.72e-05	0.00078	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—G6PD—malaria	3.69e-05	0.000774	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—SCARB1—malaria	3.6e-05	0.000755	CbGpPWpGaD
Dabrafenib—RAF1—Disease—DHFR—malaria	3.57e-05	0.000749	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—TLR4—malaria	3.57e-05	0.000748	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by FGFR in disease—IL6—malaria	3.5e-05	0.000734	CbGpPWpGaD
Dabrafenib—RAF1—Fc epsilon receptor (FCERI) signaling—IL6—malaria	3.5e-05	0.000734	CbGpPWpGaD
Dabrafenib—RAF1—DAP12 interactions—IL6—malaria	3.5e-05	0.000734	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—DHODH—malaria	3.47e-05	0.000728	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR—IL6—malaria	3.47e-05	0.000727	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by NGF—IL6—malaria	3.45e-05	0.000722	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR in Cancer—IL6—malaria	3.44e-05	0.000721	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by PDGF—IL6—malaria	3.42e-05	0.000717	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—SLC4A1—malaria	3.39e-05	0.000711	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—TLR9—malaria	3.37e-05	0.000707	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—ICAM1—malaria	3.28e-05	0.000689	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—DECR1—malaria	3.19e-05	0.000668	CbGpPWpGaD
Dabrafenib—RAF1—NGF signalling via TRKA from the plasma membrane—IL6—malaria	3.1e-05	0.00065	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—HPGDS—malaria	3.04e-05	0.000637	CbGpPWpGaD
Dabrafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—malaria	2.99e-05	0.000628	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—SLC4A1—malaria	2.95e-05	0.000619	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—HBB—malaria	2.88e-05	0.000604	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—DHFR—malaria	2.82e-05	0.000591	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—HPGDS—malaria	2.81e-05	0.00059	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—SCARB1—malaria	2.79e-05	0.000585	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—DECR1—malaria	2.78e-05	0.000582	CbGpPWpGaD
Dabrafenib—BRAF—Disease—NOS2—malaria	2.64e-05	0.000553	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—DHFR—malaria	2.61e-05	0.000547	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—CD36—malaria	2.61e-05	0.000546	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IL18—malaria	2.59e-05	0.000543	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—SCARB1—malaria	2.58e-05	0.000542	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CD40LG—malaria	2.58e-05	0.00054	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PKLR—malaria	2.57e-05	0.000539	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—IL2—malaria	2.57e-05	0.000539	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CD8A—malaria	2.55e-05	0.000534	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—CD4—malaria	2.51e-05	0.000527	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—HBB—malaria	2.51e-05	0.000526	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—HLA-B—malaria	2.45e-05	0.000514	CbGpPWpGaD
Dabrafenib—RAF1—Cytokine Signaling in Immune system—IL6—malaria	2.42e-05	0.000508	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—CD4—malaria	2.41e-05	0.000506	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CD36—malaria	2.4e-05	0.000504	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—IL6—malaria	2.38e-05	0.0005	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—G6PD—malaria	2.29e-05	0.00048	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—IL6—malaria	2.29e-05	0.00048	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—CD36—malaria	2.26e-05	0.000474	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PKLR—malaria	2.24e-05	0.000469	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CRP—malaria	2.17e-05	0.000454	CbGpPWpGaD
Dabrafenib—RAF1—Axon guidance—IL6—malaria	2.16e-05	0.000452	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—DHODH—malaria	2.14e-05	0.000449	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—TLR4—malaria	2.08e-05	0.000436	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—G6PD—malaria	2e-05	0.000418	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—ICAM1—malaria	1.99e-05	0.000418	CbGpPWpGaD
Dabrafenib—BRAF—Disease—CD4—malaria	1.95e-05	0.00041	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—KDR—malaria	1.94e-05	0.000407	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—malaria	1.92e-05	0.000403	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—TNF—malaria	1.91e-05	0.0004	CbGpPWpGaD
Dabrafenib—RAF1—Disease—NOS2—malaria	1.82e-05	0.000383	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—SLC4A1—malaria	1.82e-05	0.000381	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—CD36—malaria	1.75e-05	0.000367	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—HPGDS—malaria	1.75e-05	0.000366	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—DECR1—malaria	1.71e-05	0.000359	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—CD36—malaria	1.62e-05	0.00034	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—DHFR—malaria	1.62e-05	0.00034	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—SCARB1—malaria	1.6e-05	0.000336	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—HBB—malaria	1.55e-05	0.000324	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—IL6—malaria	1.54e-05	0.000323	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—HPGDS—malaria	1.52e-05	0.000319	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IFNG—malaria	1.52e-05	0.000318	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—IL2—malaria	1.47e-05	0.000309	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CD4—malaria	1.46e-05	0.000307	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—DHFR—malaria	1.41e-05	0.000296	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—SCARB1—malaria	1.4e-05	0.000293	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PKLR—malaria	1.38e-05	0.000289	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—IL6—malaria	1.36e-05	0.000285	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IL1B—malaria	1.35e-05	0.000283	CbGpPWpGaD
Dabrafenib—RAF1—Disease—CD4—malaria	1.35e-05	0.000283	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IL2—malaria	1.35e-05	0.000282	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—KDR—malaria	1.34e-05	0.000282	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—IL2—malaria	1.26e-05	0.000264	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—G6PD—malaria	1.23e-05	0.000258	CbGpPWpGaD
Dabrafenib—BRAF—Disease—IL6—malaria	1.06e-05	0.000222	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CD36—malaria	1.01e-05	0.000211	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—HPGDS—malaria	9.37e-06	0.000197	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CD36—malaria	8.77e-06	0.000184	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—IL2—malaria	8.71e-06	0.000183	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—DHFR—malaria	8.7e-06	0.000182	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—IL6—malaria	8.67e-06	0.000182	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—SCARB1—malaria	8.61e-06	0.00018	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IL6—malaria	7.92e-06	0.000166	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—IL6—malaria	7.4e-06	0.000155	CbGpPWpGaD
Dabrafenib—RAF1—Disease—IL6—malaria	7.31e-06	0.000153	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CD36—malaria	5.4e-06	0.000113	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—IL6—malaria	5.12e-06	0.000107	CbGpPWpGaD
